Intellia Therapeutics has dosed the first subject in a randomised, placebo-controlled global Phase III trial of its investigational CRISPR-based therapy, NTLA-2002, to treat hereditary angioedema ...

Shares of Intellia Therapeutics NTLA were down 22.9% yesterday after it announced an update from the ongoing phase III study, ...

Intellia Therapeutics, Inc. announced the dosing of the first patient in the global Phase 3 study for NTLA-2002, a CRISPR-based therapy aimed at treating hereditary angioedema (HAE). This ...

Strategic focus on developing NTLA-2002 and nex-z, which are expected to create significant near-term value, highlighting the company’s commitment to addressing unmet medical needs in hereditary ...

Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment ...

NTLA-2002 is a wholly owned investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for this potentially life-threatening disease. Patient screening is ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) traded lower by as much as 20% the other day because of the data it released from the phase 1/2 study using its CRISPR/Cas9 gene editing drug NTLA-2002 ...

I'm pleased to welcome you to Intellia's conference call to discuss the results from the NTLA-2002 Phase 2 study. Earlier today, Intellia issued a press release detailing these data, which were ...

NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9. NTLA-2002 targets the gene encoding ...

NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent potentially life-threatening swelling attacks in people with HAE. “The European Union orphan drug designation for ...

NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a one-time treatment for HAE, a rare genetic condition that leads to potentially life-threatening ...